GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region
Despite these cardioprotective agents being recommended by guidelines, the study findings suggest a suboptimal use of GLP-1RA and SGLT2i in a real-world setting.
Authors
- Naji Alamuddin
- Amin Jayyousi (ORCID: https://orcid.org/0000-0003-3174-3037)
- Shashikanth Chetty
- Jehan Abdulla (ORCID: https://orcid.org/0000-0003-0393-9139)
- Hessa M. al Kandari
- Dalal Alromaihi (ORCID: https://orcid.org/0000-0001-8470-6286)
- Mashhood A. Siddique
- Dulcinéia Saes Parra Abdalla (ORCID: https://orcid.org/0000-0001-9608-3135)
- Waleed A. Al-Dahi
- Usama AlAlami (ORCID: https://orcid.org/0009-0008-8485-894X)
- Saeed Khalaf
- Guruprasad Subbarao
- Hanan Y. Alfadehla
Institutions
- University of Bahrain (BH)
- Al Yarmouk University College (IQ)
- Salmaniya Medical Complex (BH)
- Mubarak Al Kabeer Hospital (KW)
- Farwaniya Hospital (KW)
- Primary HealthCare (MT)
- Primary Health Care (QA)
- King Hamad University Hospital (BH)
- Dasman Diabetes Institute (KW)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- Saudi Medical Journal
- Published
- 2025-02-01
- DOI
- https://doi.org/10.15537/smj.2025.46.2.20240620
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18